Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 6/2011

01-12-2011 | Original Article

Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation

Authors: Cristina P. R. Xavier, Cristovao F. Lima, Mikkel Rohde, Cristina Pereira-Wilson

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2011

Login to get access

Abstract

Purpose

Colorectal tumors (CRC) with microsatellite instability (MSI) show resistance to chemotherapy with 5-fluorouracil (5-FU), the most widely used pharmacological drug for CRC treatment. The aims of this study were to test the ability of quercetin (Q) and luteolin (L) to increase the sensitivity of MSI CRC cells to 5-FU and characterize the dependence of the effects on cells’ p53 status.

Methods

Two MSI human CRC-derived cell lines were used: CO115 wild type (wt) for p53 and HCT15 that harbors a p53 mutation. Apoptosis induction in these cells by 5-FU, Q and L alone, and in combinations was evaluated by TUNEL and western blot. The dependence of the effects on p53 was confirmed by small interference RNA (siRNA) in CO115 cells and in MSI HCT116 wt and p53 knockout cells.

Results

CO115 p53-wt cells are more sensitive to 5-FU than the p53-mutated HCT15. The combination treatment of 5-FU with L and Q increased apoptosis with a significant effect for Q in CO115. Both flavonoids increased p53 expression in both cell lines, an effect particularly remarkable for Q. The significant apoptotic enhancement in CO115 incubated with Q plus 5-FU involved the activation of the apoptotic mitochondrial pathway. Importantly, knockdown of p53 by siRNA in CO115 cells and p53 knockout in HCT116 cells totally abrogated apoptosis induction, demonstrating the dependence of the effect on p53 modulation by Q.

Conclusion

This study suggests the potential applicability of these phytochemicals for enhancement 5-FU efficiency in MSI CRC therapy, especially Q in p53 wt tumors.
Literature
1.
go back to reference Rupnarain C, Dlamini Z, Naicker S, Bhoola K (2004) Colon cancer: genomics and apoptotic events. Biol Chem 385:449–464PubMedCrossRef Rupnarain C, Dlamini Z, Naicker S, Bhoola K (2004) Colon cancer: genomics and apoptotic events. Biol Chem 385:449–464PubMedCrossRef
2.
go back to reference Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257PubMedCrossRef Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257PubMedCrossRef
3.
go back to reference Bhushan S, McLeod H, Walko CM (2009) Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer 8:15–21PubMedCrossRef Bhushan S, McLeod H, Walko CM (2009) Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer 8:15–21PubMedCrossRef
4.
5.
6.
go back to reference Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22:1470–1479 Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22:1470–1479
7.
go back to reference Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848–855PubMedCrossRef Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848–855PubMedCrossRef
8.
go back to reference Warusavitarne J, Schnitzler M (2007) The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22:739–748PubMedCrossRef Warusavitarne J, Schnitzler M (2007) The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22:739–748PubMedCrossRef
9.
go back to reference Soreide K, Janssen EA, Soiland H, Korner H, Baak JP (2006) Microsatellite instability in colorectal cancer. Br J Surg 93:395–406PubMedCrossRef Soreide K, Janssen EA, Soiland H, Korner H, Baak JP (2006) Microsatellite instability in colorectal cancer. Br J Surg 93:395–406PubMedCrossRef
10.
go back to reference Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369–373PubMedCrossRef Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369–373PubMedCrossRef
11.
go back to reference Seruca R, Velho S, Oliveira C, Leite M, Matos P, Jordan P (2009) Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. Expert Rev Gastroenterol Hepatol 3:5–9PubMedCrossRef Seruca R, Velho S, Oliveira C, Leite M, Matos P, Jordan P (2009) Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. Expert Rev Gastroenterol Hepatol 3:5–9PubMedCrossRef
12.
go back to reference Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190–192PubMedCrossRef Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190–192PubMedCrossRef
13.
go back to reference Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T (2002) Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98:498–504PubMedCrossRef Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T (2002) Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98:498–504PubMedCrossRef
14.
go back to reference Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMedCrossRef Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMedCrossRef
15.
go back to reference Adamsen BL, Kravik KL, Clausen OP, De Angelis PM (2007) Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31:1491–1500PubMed Adamsen BL, Kravik KL, Clausen OP, De Angelis PM (2007) Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31:1491–1500PubMed
16.
go back to reference Mori S, Ogata Y, Shirouzu K (2004) Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 9:322–329PubMedCrossRef Mori S, Ogata Y, Shirouzu K (2004) Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 9:322–329PubMedCrossRef
17.
go back to reference Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta 1795:117–129PubMed Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta 1795:117–129PubMed
18.
go back to reference Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421PubMedCrossRef Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421PubMedCrossRef
19.
go back to reference Ramos S (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52:507–526PubMedCrossRef Ramos S (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52:507–526PubMedCrossRef
20.
go back to reference Subapriya Rajamanickam RA (2008) Natural products and colon cancer: current status and future prospects. Drug Dev Res 69:460–471PubMedCrossRef Subapriya Rajamanickam RA (2008) Natural products and colon cancer: current status and future prospects. Drug Dev Res 69:460–471PubMedCrossRef
21.
go back to reference Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537–549PubMedCrossRef Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537–549PubMedCrossRef
22.
23.
go back to reference Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15:369–379PubMedCrossRef Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15:369–379PubMedCrossRef
24.
go back to reference Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, Pereira-Wilson C (2009) Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281:162–170PubMedCrossRef Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, Pereira-Wilson C (2009) Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281:162–170PubMedCrossRef
25.
go back to reference Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20:5025–5032PubMedCrossRef Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20:5025–5032PubMedCrossRef
26.
go back to reference Barbour KW, Berger FG (2008) Cell death in response to antimetabolites directed at thymidylate synthase. Cancer Chemother Pharmacol 61:189–201PubMedCrossRef Barbour KW, Berger FG (2008) Cell death in response to antimetabolites directed at thymidylate synthase. Cancer Chemother Pharmacol 61:189–201PubMedCrossRef
27.
go back to reference Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRef Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRef
28.
go back to reference Preto A, Figueiredo J, Velho S, Ribeiro A, Soares P, Oliveira C, Seruca R (2008) BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214:320–327PubMedCrossRef Preto A, Figueiredo J, Velho S, Ribeiro A, Soares P, Oliveira C, Seruca R (2008) BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214:320–327PubMedCrossRef
29.
go back to reference Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M (2002) Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94:3127–3134PubMedCrossRef Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M (2002) Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94:3127–3134PubMedCrossRef
30.
go back to reference Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667–676PubMedCrossRef Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667–676PubMedCrossRef
31.
go back to reference Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM (2006) Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243:833–842 discussion 843–844PubMedCrossRef Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM (2006) Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243:833–842 discussion 843–844PubMedCrossRef
32.
go back to reference Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350–356PubMedCrossRef Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350–356PubMedCrossRef
33.
go back to reference McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279PubMedCrossRef McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279PubMedCrossRef
34.
go back to reference Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL (2007) Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 83:338–343PubMedCrossRef Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL (2007) Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 83:338–343PubMedCrossRef
35.
go back to reference Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG (2007) Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 13:1534–1540PubMedCrossRef Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG (2007) Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 13:1534–1540PubMedCrossRef
36.
go back to reference Wang CZ, Luo X, Zhang B, Song WX, Ni M, Mehendale S, Xie JT, Aung HH, He TC, Yuan CS (2007) Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol 60:69–79PubMedCrossRef Wang CZ, Luo X, Zhang B, Song WX, Ni M, Mehendale S, Xie JT, Aung HH, He TC, Yuan CS (2007) Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol 60:69–79PubMedCrossRef
37.
go back to reference Shi R, Huang Q, Zhu X, Ong YB, Zhao B, Lu J, Ong CN, Shen HM (2007) Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 6:1338–1347PubMedCrossRef Shi R, Huang Q, Zhu X, Ong YB, Zhao B, Lu J, Ong CN, Shen HM (2007) Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 6:1338–1347PubMedCrossRef
38.
go back to reference Hou Q (2008) Effect of staurosporine induced apoptosis of MCF7/GFP-Bax stable cell line on Bax translocation from cytosol into mitochondria. Yao Xue Xue Bao 43:378–382PubMed Hou Q (2008) Effect of staurosporine induced apoptosis of MCF7/GFP-Bax stable cell line on Bax translocation from cytosol into mitochondria. Yao Xue Xue Bao 43:378–382PubMed
Metadata
Title
Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation
Authors
Cristina P. R. Xavier
Cristovao F. Lima
Mikkel Rohde
Cristina Pereira-Wilson
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1641-9

Other articles of this Issue 6/2011

Cancer Chemotherapy and Pharmacology 6/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine